HC Wainwright Has Bearish Estimate for KYTX FY2026 Earnings

Kyverna Therapeutics, Inc. (NASDAQ:KYTX – Free Report) – HC Wainwright cut their FY2026 earnings per share estimates for shares of Kyverna Therapeutics in a report issued on Friday, November 13th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings of ($2.71) per share for the year, down from their previous forecast of ($2.70). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Kyverna Therapeutics’ current full-year earnings is ($2.71) per share. HC Wainwright also issued estimates for Kyverna Therapeutics’ Q4 2027 earnings at ($0.53) EPS and FY2027 earnings at ($2.78) EPS.

Kyverna Therapeutics (NASDAQ:KYTX – Get Free Report) last released its quarterly earnings results on Thursday, November 12th. The company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($0.69) by $0.01.

A number of other research analysts have also recently weighed in on the company. Benchmark restated a “buy” rating on shares of Kyverna Therapeutics in a research report on Friday, September 25th. Needham & Company LLC set a $25.00 price objective on shares of Kyverna Therapeutics in a research report on Friday, September 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Kyverna Therapeutics in a research note on Monday, September 21st. Finally, William Blair raised shares of Kyverna Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 23rd. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $29.00.

Check Out Our Latest Stock Report on Kyverna Therapeutics

Kyverna Therapeutics Stock Performance

NASDAQ:KYTX opened at $4.48 on Tuesday. The company has a quick ratio of 7.01, a current ratio of 7.01 and a debt-to-equity ratio of 0.19. Kyverna Therapeutics has a fifty-two week low of $4.40 and a fifty-two week high of $13.67. The stock has a market cap of $283.23 million, a PE ratio of -1.62 and a beta of 2.12. The firm’s fifty day simple moving average is $6.02 and its 200-day simple moving average is $7.83.

Institutional Investors Weigh In On Kyverna Therapeutics

Hedge funds have recently modified their holdings of the stock. Aquatic Capital Management LLC acquired a new position in Kyverna Therapeutics in the third quarter valued at $488,000. Goldman Sachs Group Inc. increased its stake in Kyverna Therapeutics by 64.6% during the third quarter. Goldman Sachs Group Inc. now owns 551,899 shares of the company’s stock worth $3,753,000 after acquiring an additional 216,669 shares during the last quarter. Marshall Wace LLP purchased a new position in shares of Kyverna Therapeutics in the 3rd quarter worth about $498,000. Empowered Funds LLC purchased a new position in shares of Kyverna Therapeutics in the 3rd quarter worth about $127,000. Finally, Kovack Advisors Inc. purchased a new position in shares of Kyverna Therapeutics in the 3rd quarter worth about $65,000. 18.08% of the stock is owned by institutional investors and hedge funds.

About Kyverna Therapeutics

(Get Free Report)

Kyverna Therapeutics is a clinical-stage biopharmaceutical company developing cell therapies for people with autoimmune diseases. The company’s approach aims to use engineered immune cells to address disease-causing B cells. Its lead candidate, KYV-101, is an autologous CAR T-cell therapy designed to target CD19, a protein found on B cells. Kyverna is evaluating the therapy in clinical studies for several autoimmune conditions, including stiff person syndrome, myasthenia gravis and lupus nephritis.

Recommended Stories

Earnings History and Estimates for Kyverna Therapeutics (NASDAQ:KYTX)

Receive News & Ratings for Kyverna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kyverna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.